V - Why Moderna Stock Is Up
In this episode of Market Foolery, Chris Hill chats with Motley Fool analyst Emily Flippen about the latest headlines and earnings reports from Wall Street. Moderna (NASDAQ: MRNA) enters a new phase in its COVID-19 vaccine trials. A popular toymaker's stock gets a steep cut. Finally, the hosts answer some listener questions about portfolio allocation and retail investment in a post-COVID-19 world.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.